Evaluating the Cologuard Test for Use in Lynch Syndrome

Related Clinical Trial
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. DNA Adductomics for Colorectal Cancer Investigation PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Faecal Microbiota Characterization in Lynch Syndrome (LS) Patients With or Without Colorectal Neoplasia Evaluating the Cologuard Test for Use in Lynch Syndrome PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome Identifying and Caring for Individuals With Inherited Cancer Syndrome Predictive Factor Study of the Occurrence of Endometrial Cancer in Patients With Lynch Syndrome Liquid Biopsy Evaluation and Repository Development at Princess Margaret Direct Information to At-risk Relatives Family History Study on Cancer Risk Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Biomarkers in Samples From Patients With Endometrial Cancer Genetic Risk: Whether, When, and How to Tell Adolescents Familial Colorectal Cancer Registry in Hispanics Prostate Cancer Screening Among Men With High Risk Genetic Predisposition Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool Pediatric Reporting of Adult-Onset Genomic Results Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants MSI in Circulatory DNA of Endometrial Cancer Telemedicine vs. Face-to-Face Cancer Genetic Counseling Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer Implementation of a New Strategy to Identify HNPCC Patients Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes The GEOLynch Cohort Study Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome I-Scan For Colon Polyp Detection In HNPCC Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer Ohio Colorectal Cancer Prevention Initiative Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Molecular Screening for Lynch Syndrome in Denmark Atorvastatin ± Aspirin in Lynch Syndrome Syndrome Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Uncertain Genetic Test Results for Lynch Syndrome High Definition White-Light Colonoscopy vs. Chromoendoscopy for Surveillance of Lynch Syndrome. Linked Color Imaging Versus High-definition White Light Endoscopy for the Detection of Polyps in Patients With Lynch Syndrome (LCI-LYNCH) Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications Molecular Screening for Lynch Syndrome in Southern Denmark Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer Multi-Organ Screening Recommendations in Patients With Lynch Syndrome Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting Registry for Women Who Are At Risk Or May Have Lynch Syndrome

Brief Title

Evaluating the Cologuard Test for Use in Lynch Syndrome

Official Title

Evaluating the Cologuard Test for Use in Lynch Syndrome

Brief Summary

      This study is aiming to enroll 90 patients with genetically confirmed Lynch Syndrome (LS)
      from Geisinger's High Risk Colorectal Cancer Clinic (HRC). Upon enrollment in the study, a
      Cologuard test will be ordered and the results will be blinded until data analysis. Patients
      enrolled in the study will also undergo a colonoscopy as part of their routine HRC visit.

Detailed Description

      The primary aim is to perform a pilot study to gain information toward the implementation of
      a larger prospective study that will compare the performance of Cologuard with the
      gold-standard colonoscopy in identifying advanced adenomas and colorectal cancers in LS. Data
      regarding rate of consent, and adherence to the protocol will be recorded. Since patients
      with known genetic predisposition to cancers tend to view screening tests more positively
      than the general population, a second aim of the study is to evaluate patient satisfaction
      with bowel preparation, colonoscopies, and Cologuard testing. Up to 90 individuals with
      genetically confirmed LS will be recruited via Geisinger's HRC to complete a goal of 90
      Cologuard studies. Upon enrollment, Cologuard will be ordered by the study team at no cost to
      the subject and will be completed according to the standard instructions for use. Results
      will be securely obtained and blinded until the time of data analysis. Subjects will undergo
      colonoscopy as part of their routine HRC visit. Results from the colonoscopy (and biopsy as
      indicated) will be retrieved from the Electronic Health Record (EHR) and documented in a
      research-associated spreadsheet. If repeat colonoscopy is clinically indicated, repeat
      Cologuard may be completed if the subject meets inclusion criteria.

Study Type


Primary Outcome

Evaluate the feasibility of the Cologuard test for Lynch Syndrome

Secondary Outcome

 Evaluate patient satisfaction with Cologuard


Lynch Syndrome


Cologuard test

Study Arms / Comparison Groups

 Cologuard Study Group
Description:  Within 60 days of their already scheduled screening colonoscopy, participants will provide a stool sample to be tested by a Cologuard screening test kit. Participants will also complete surveys prior to their colonoscopy as well as post colonoscopy.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Diagnostic Test

Estimated Enrollment


Start Date

June 2021

Completion Date

September 2022

Primary Completion Date

May 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Patients age 18-89

          -  Diagnosis of genetically confirmed LS

          -  Scheduled for standard of care colonoscopy within 60 days of enrollment

        Exclusion Criteria:

          -  Diagnosis of other inherited genetic disorders that increase risk for Colorectal
             Cancer (CRC) (Familial Adenomatous Polyposis (FAP), Cowden's syndrome, Turcot
             syndrome, Gardner syndrome, and Peutz-Jeghers syndrome)

          -  Diagnosis of other inherited Inflammatory bowel disease (i.e. Crohn disease,
             ulcerative colitis)

          -  Others with elevated risk of CRC outside of the inclusion criteria (i.e. ≥2
             first-degree relatives who have been diagnosed with CRC without a defined inherited
             genetic disorder, Hereditary Non-Polyposis Colon Cancer (HNPCC) without genetic
             confirmation of LS)

          -  Participation in any interventional clinical study within the previous 30 days

          -  Personal history of CRC not in full remission (5 consecutive cancer-free years)

          -  Current active treatment with chemotherapy

          -  Treatment with chemotherapy within 12 months prior to consent date




18 Years - 89 Years

Accepts Healthy Volunteers



Rajiv Panikkar, MD, 5702716834, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Geisinger Clinic

Study Sponsor

Rajiv Panikkar, MD, Principal Investigator, Geisinger Clinic

Verification Date

May 2021